Narendranath Epperla, MD, MS, FACP Profile
Narendranath Epperla, MD, MS, FACP

@NEpperla

Followers
257
Following
358
Media
1
Statuses
178

Lymphoma specialist at HCI

Salt Lake City, UT
Joined July 2017
Don't wanna be here? Send us removal request.
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
5 months
RT @KepecsLab: 1/ Why do late-stage cancer patients lose motivation & sink into apathy?.🔥Our new Science paper shows cancer activates a cyt….
Tweet card summary image
science.org
Cachexia, a severe wasting syndrome associated with inflammatory conditions, often leads to multiorgan failure and death. Patients with cachexia experience extreme fatigue, apathy, and clinical...
0
62
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
5 months
RT @RShouval: 🚨 Just out @NatureMedicine!.Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive….
Tweet card summary image
nature.com
Nature Medicine - A preinfusion circulatory inflammation biomarker-based signature predicts the likelihood of treatment failure in patients with non-Hodgkin lymphoma who were treated with CAR-T...
0
42
0
@grok
Grok
@grok
4 days
Join millions who have switched to Grok.
177
357
3K
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
5 months
RT @Transplant_Doc: Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies #mmsm #bmtsm @DrMarc….
jhoonline.biomedcentral.com
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma...
0
8
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
7 months
RT @NatRevCardiol: New online! Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment htt….
0
59
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
8 months
RT @UofU3i: New 3i Investigator Article Alert!! Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagno….
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample...
0
2
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
8 months
RT @NEJMEvidence: In this statistical editorial, Larry Han, PhD, reviews the concept of left truncation in time-to-event studies. Read the….
0
9
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
9 months
RT @johnvaughnmd: Happy to share this new study out in @BloodCancerJnl, coauthored by @NEpperla.
nature.com
Blood Cancer Journal - A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study
0
4
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
9 months
RT @BloodAdvances: The study shows the safety and long-term efficacy of auto-HCT, even in patients with high-risk cHL who are traditionally….
0
13
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
11 months
RT @md_addison: Cardiac considerations with Emerging Cancer Cellular Therapies:. Thanks @BloodAdvances for publish….
0
15
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
1 year
RT @AbhiLenka11: Exciting discovery: CSF flow isn't confined to the brain and spinal cord—it also extends to peripheral nerves! @ScienceMag….
0
381
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
1 year
RT @johnvaughnmd:
Tweet card summary image
nejm.org
The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern. We reviewed our ...
0
1
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
1 year
RT @majorajay: Multicenter CNS involvement in HGBL NOS @NEpperla:.- 160 pts, 7% baseline CNSi.- CNSi➡️MYC-R, testicular/female pelvic.- no….
0
7
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
2 years
RT @DrAEvens: We are looking forward to working on this more- adding ⬆️ cases & analyses (45-49% vs <45% split was arbitrary but may be rel….
0
2
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
2 years
RT @PatrickHwuMD: #ScienceSaturday Can dietary nutrients help the immune system kill #cancer cells? In this study, researchers screened 25….
0
32
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
2 years
RT @UsuarezMD: Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort….
ashpublications.org
TO THE EDITOR:
0
1
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
2 years
RT @Eddie_Cliff: #ASH23 Late breaking abstract 2. The long-awaited SYMPATICO trial. Ibr+Ven vs Ibr+pbo RCT in R/R MCL.- med PFS 31.9 vs 22.….
0
13
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
2 years
RT @BroeckelmannPJ: Genetic-subtype guided R-CHOP-X treatment resulted in superior DLBCL outcomes vs R-CHOP in the randomized phase 2 GUIDA….
0
72
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
2 years
RT @BLLPHD: Beyond youth: Understanding CAR T cell fitness in the context of immunological aging - NEW by @jh_noll 🧵.
0
21
0
@NEpperla
Narendranath Epperla, MD, MS, FACP
@NEpperla
2 years
RT @ASTCT_Journal: A new guideline from @ASTCT provides clinical practice recommendations for transplant and cellular therapies in diffuse….
0
23
0